Retrophin (RTRX) Receives Analyst Rating

Retrophin (RTRX) : 2 brokerage houses believe that Retrophin (RTRX) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 2 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Retrophin (RTRX) : 2 Wall Street analysts covering Retrophin (RTRX) believe that the average level the stock could reach for the short term is $28.5. The maximum price target given is $32 and the minimum target for short term is around $25, hence the standard deviation is calculated at $4.95.


Retrophin (NASDAQ:RTRX): After opening at $23.27, the stock dipped to an intraday low of $23.1479 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $24.315 and the buying power remained strong till the end. The stock closed at $24.23 for the day, a gain of 4.17% for the day session. The total traded volume was 605,771. The stocks close on the previous trading day was $23.26.

Retrophin, Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children, including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound, Sparsentan, for FSGS. The Companys products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034, which are in pre-clinical stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.